AcelRx Pharmaceuticals (ACRX) Sees Large Volume Increase After Analyst Upgrade

Share on StockTwits

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) shares saw an uptick in trading volume on Monday after Cantor Fitzgerald raised their price target on the stock from $8.00 to $9.00. Cantor Fitzgerald currently has an overweight rating on the stock. 9,511,175 shares were traded during mid-day trading, an increase of 39% from the previous session’s volume of 6,833,616 shares.The stock last traded at $4.38 and had previously closed at $4.80.

A number of other equities research analysts also recently commented on ACRX. ValuEngine upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, November 2nd. LADENBURG THALM/SH SH set a $10.00 price target on shares of AcelRx Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, November 2nd. Oppenheimer reiterated a “hold” rating on shares of AcelRx Pharmaceuticals in a research report on Friday, August 3rd. Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.00 price target for the company in a research report on Tuesday, July 10th. Finally, HC Wainwright reiterated a “buy” rating on shares of AcelRx Pharmaceuticals in a research report on Tuesday, August 7th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $7.93.

In other news, insider Badri N. Dasu sold 28,351 shares of the business’s stock in a transaction on Monday, October 15th. The shares were sold at an average price of $5.00, for a total transaction of $141,755.00. Following the completion of the sale, the insider now directly owns 54,061 shares of the company’s stock, valued at approximately $270,305. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Lawrence G. Hamel sold 6,953 shares of the company’s stock in a transaction on Monday, September 24th. The stock was sold at an average price of $4.50, for a total transaction of $31,288.50. Following the sale, the insider now directly owns 24,371 shares of the company’s stock, valued at $109,669.50. The disclosure for this sale can be found here. 25.50% of the stock is owned by insiders.

A number of hedge funds have recently modified their holdings of ACRX. Northern Trust Corp raised its stake in shares of AcelRx Pharmaceuticals by 60.8% in the 1st quarter. Northern Trust Corp now owns 91,481 shares of the specialty pharmaceutical company’s stock valued at $192,000 after purchasing an additional 34,584 shares in the last quarter. Lincoln Capital Corp bought a new stake in shares of AcelRx Pharmaceuticals during the 2nd quarter valued at about $116,000. Granite Investment Partners LLC bought a new stake in shares of AcelRx Pharmaceuticals during the 2nd quarter valued at about $182,000. BlackRock Inc. grew its position in shares of AcelRx Pharmaceuticals by 2.7% during the 2nd quarter. BlackRock Inc. now owns 673,115 shares of the specialty pharmaceutical company’s stock valued at $2,271,000 after buying an additional 17,737 shares during the last quarter. Finally, FMR LLC grew its position in shares of AcelRx Pharmaceuticals by 1,094.6% during the 2nd quarter. FMR LLC now owns 298,644 shares of the specialty pharmaceutical company’s stock valued at $1,008,000 after buying an additional 273,644 shares during the last quarter. Hedge funds and other institutional investors own 8.58% of the company’s stock.

The stock has a market cap of $290.88 million, a price-to-earnings ratio of -3.55 and a beta of 2.03.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its quarterly earnings data on Monday, November 5th. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The company had revenue of $0.38 million for the quarter, compared to analyst estimates of $1.10 million. Equities analysts predict that AcelRx Pharmaceuticals Inc will post -0.82 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “AcelRx Pharmaceuticals (ACRX) Sees Large Volume Increase After Analyst Upgrade” was first reported by Week Herald and is owned by of Week Herald. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://weekherald.com/2018/11/07/acelrx-pharmaceuticals-acrx-sees-large-volume-increase-after-analyst-upgrade.html.

About AcelRx Pharmaceuticals (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Featured Story: Cost of Capital Explained

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply